Global Peptide Drug CDMO Market Growth (Status and Outlook) 2026-2032
Description
The global Peptide Drug CDMO market size is predicted to grow from US$ 2945 million in 2025 to US$ 5834 million in 2032; it is expected to grow at a CAGR of 10.5% from 2026 to 2032.
Peptide CDMO refers to an organization that accepts commissions from pharmaceutical companies and engages in the development and production of peptide drugs. These organizations usually have advanced peptide synthesis, purification, analysis and other technologies, and can provide customers with one-stop services from peptide API synthesis, purification, structural identification to formulation development, clinical trials, etc.
As a unique drug compound, peptides are between small molecules and proteins, and are different in biochemistry and treatment. Peptides provide opportunities for therapeutic interventions that closely mimic natural pathways and play a major role in various physiological processes in the human body (including hormones, neurotransmitters) or in inflammatory responses. Peptide drugs have the characteristics of strong selectivity and rapid onset, and can be extracted naturally or synthesized artificially. With multiple advantages such as high purity and controllable quality, they have become popular drugs at present. The medical field is an important application market for peptide substances, and the market demand for peptide drugs is increasing. Based on the complexity and high-tech characteristics of peptide drug development, peptide development and production outsourcing services came into being, that is, peptide CDMO began to appear.
United States market for Peptide Drug CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Peptide Drug CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Peptide Drug CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Peptide Drug CDMO players cover Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Peptide Drug CDMO Industry Forecast” looks at past sales and reviews total world Peptide Drug CDMO sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide Drug CDMO sales for 2026 through 2032. With Peptide Drug CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Drug CDMO industry.
This Insight Report provides a comprehensive analysis of the global Peptide Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide Drug CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Drug CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Drug CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Drug CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
APIs and Intermediates
FDF
Segmentation by Application:
Antineoplastic Drugs
Geno-Urinary System and Sex Hormones
Cardiovascular System Drugs
Anti-Infective Drugs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Please note: The report will take approximately 2 business days to prepare and deliver.
Peptide CDMO refers to an organization that accepts commissions from pharmaceutical companies and engages in the development and production of peptide drugs. These organizations usually have advanced peptide synthesis, purification, analysis and other technologies, and can provide customers with one-stop services from peptide API synthesis, purification, structural identification to formulation development, clinical trials, etc.
As a unique drug compound, peptides are between small molecules and proteins, and are different in biochemistry and treatment. Peptides provide opportunities for therapeutic interventions that closely mimic natural pathways and play a major role in various physiological processes in the human body (including hormones, neurotransmitters) or in inflammatory responses. Peptide drugs have the characteristics of strong selectivity and rapid onset, and can be extracted naturally or synthesized artificially. With multiple advantages such as high purity and controllable quality, they have become popular drugs at present. The medical field is an important application market for peptide substances, and the market demand for peptide drugs is increasing. Based on the complexity and high-tech characteristics of peptide drug development, peptide development and production outsourcing services came into being, that is, peptide CDMO began to appear.
United States market for Peptide Drug CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Peptide Drug CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Peptide Drug CDMO is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Peptide Drug CDMO players cover Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Peptide Drug CDMO Industry Forecast” looks at past sales and reviews total world Peptide Drug CDMO sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide Drug CDMO sales for 2026 through 2032. With Peptide Drug CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Drug CDMO industry.
This Insight Report provides a comprehensive analysis of the global Peptide Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide Drug CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Drug CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Drug CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Drug CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
APIs and Intermediates
FDF
Segmentation by Application:
Antineoplastic Drugs
Geno-Urinary System and Sex Hormones
Cardiovascular System Drugs
Anti-Infective Drugs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
108 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Peptide Drug CDMO Market Size by Player
- 4 Peptide Drug CDMO by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Peptide Drug CDMO Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
